集团自主研发的国家1类创新药TRD208在中国开展的I期临床试验已顺利完成首例患者入组。TRD208是 一款全球首创的非阿片类多靶点多模式镇痛创新药，有望成为急性疼痛领域的重磅药物。 临床前数据表明，TRD208在术后痛模型中表现出快速起效、强效镇痛、时间持久的优势。作为具有多 靶点协同作用的非阿片类药物，TRD208有望首次实现单一药物达到多模式镇痛的效果，进而替代目前 临床主流的联合用药方案，满足镇痛全过程的临床需求，具有简化治疗方案、提升患者用药依从性、规 避阿片类药物成瘾与依赖风险的核心优势。 智通财经APP讯，中国生物制药(01177)公布，该集团自主研发的国家1类创新药TRD208在中国开展的I 期临床试验已顺利完成首例患者入组。TRD208是一款全球首创的非阿片类多靶点多模式镇痛创新药， 有望成为急性疼痛领域的重磅药物。 ...

中国生物制药(01177)公布，该集团自主研发的国家1类创新药TRD208在中国开展的I期临床试验已顺利 完成首例患者入组。TRD208是一款全球首创的非阿片类多靶点多模式镇痛创新药，有望成为急性疼痛 领域的重磅药物。 集团自主研发的国家1类创新药TRD208在中国开展的I期临床试验已顺利完成首例患者入组。TRD208是 一款全球首创的非阿片类多靶点多模式镇痛创新药，有望成为急性疼痛领域的重磅药物。 临床前数据表明，TRD208在术后痛模型中表现出快速起效、强效镇痛、时间持久的优势。作为具有多 靶点协同作用的非阿片类药物，TRD208有望首次实现单一药物达到多模式镇痛的效果，进而替代目前 临床主流的联合用药方案，满足镇痛全过程的临床需求，具有简化治疗方案、提升患者用药依从性、规 避阿片类药物成瘾与依赖风险的核心优势。 ...

生物科技ETF价值凸显，但慎防短期溢价风险。 作者 | RAYYYY 编辑 | 小白 刚刚过去的11月，生物科技ETF成为市场最大赢家。 Choice数据显示，纳指生物科技ETF（513290.SH）和标普生物科技ETF（159502.SZ）分别以显著涨 幅位居全市场ETF月度涨幅排名第一、第二位，这一强劲表现凸显了生物科技板块在当前市场环境下 的投资价值。 | | | 11月ETF涨幅榜TOP10(规模大于1亿) | | | | --- | --- | --- | --- | --- | | 证券代码 | 证券名称 | 跟踪指数名称 | 基金规模合并值(亿元) 11月涨跌幅(%) | | | 159502. SZ | 标普生物科技ETF | 标普生物科技精选行业指数 | 22. 08 | 14. 03 | | 513290. SH | 纳指生物科技ETF | 纳斯达克生物科技指数 | 15. 37 | 12. 83 | | 513350. SH | 标普油气ETF | S&P Oil & Gas Exploration & Production Select Industry | 6. 19 | 4. 30 ...

Core Insights - The company is focusing on maintaining stable growth in its traditional business while expanding into innovative drug development, particularly in the field of growth hormones and fertility treatments [6][7]. Group 1: Sales Strategy and Market Positioning - The company plans to leverage its established marketing team and extensive hospital coverage to ensure steady sales growth in growth hormones, despite a decline in newborn numbers [2]. - The collaboration with Weisheng Pharmaceutical for the long-acting growth hormone, Longpei, is positioned as a high-quality product with a unique market advantage due to its clinical validation [3]. - The company is actively promoting its long-acting follicle-stimulating hormone, Shengnuowa, through various sales channels, including private hospitals, which are not restricted by regulatory hurdles [4]. Group 2: Research and Development Progress - The company is advancing its dual-target Her2 and PD-L1*4-1BB dual antibody drugs, with plans for non-clinical research and IND application in the coming years [5]. - The establishment of the Anke Biological Innovation Research Institute aims to attract top talent and enhance R&D capabilities to overcome current research bottlenecks [6][7]. Group 3: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 1.963 billion yuan, a year-on-year increase of 2.15%, while net profit decreased by 6.48% to 551 million yuan [8]. - The third quarter alone saw a revenue of 670 million yuan, reflecting a 7.7% year-on-year increase, with net profit rising by 6.56% to 185 million yuan [8].

Summary of FOSUN International Conference Call Company Overview - **Company**: FOSUN International - **Industry**: Diversified Investments, Pharmaceuticals, Insurance, Consumer Goods Key Points Strategic Transformation - FOSUN International is undergoing a strategic transformation focusing on core businesses and exiting non-core assets, aiming to increase overseas revenue contribution to 60% and significantly reduce debt levels, targeting interest-bearing liabilities below 60 billion RMB and public market debt to 25% [2][6][3] Business Segments - **Domestic Business**: - Focus on consumer sectors, including gold jewelry and cultural tourism through Yuyuan [4] - Innovation in pharmaceuticals represented by FOSUN Pharma [4][5] - **Overseas Business**: - Key investments in Portuguese insurance and consumer brands like Club Med, contributing to nearly 30% of total overseas revenue [4][10] Financial Goals - Plans to reduce interest-bearing debt from a peak of 120 billion RMB to 89 billion RMB, with a further target of 60 billion RMB [6] - Aiming to restore group operating profit and net profit attributable to shareholders to 10 billion RMB, while gradually increasing the dividend payout ratio from 20% to 50% over the next 3-5 years [6][13] Innovation in Pharmaceuticals - FOSUN Pharma is accelerating its transition to innovative drugs, with expectations for rapid growth post-2027, supported by a global R&D center and innovative drug platform [2][9] - Currently, there are multiple innovative drugs in the pipeline with global sales potential between 5 billion to 10 billion USD [9] Geographic Risk Management - The company employs a strategy combining globalization with local operations to mitigate geopolitical risks, particularly in Europe and North America [7][11] - In Europe, the Portuguese insurance business is expected to maintain a premium income growth rate of 10%-15% over the next five years, with significant profit growth potential due to low current ROE [10] Asset Disposal Strategy - FOSUN International has identified approximately 90 billion to 100 billion RMB worth of assets for disposal, including real estate and non-core investments, aiming to generate cash flow to reduce debt [12] - Specific assets include real estate valued at around 30 billion RMB and non-core secondary market holdings [12] Dividend Policy - The company plans to gradually increase its dividend payout ratio to enhance shareholder returns, with a target of achieving 10 billion RMB in operating profit [13] Competitive Position in Pharmaceuticals - FOSUN Pharma is transitioning from generics to innovative drugs, with significant investments in R&D and a focus on global commercialization capabilities [14][15] - The company is committed to maintaining a competitive edge through substantial annual investments in innovation and development [15] Real Estate Disposal Insights - The company evaluates real estate project sales based on market conditions and potential for appreciation, indicating a flexible pricing strategy [16]

Core Viewpoint - The announcement details the progress of the clinical research for the innovative drug 9MW1911 developed by Maiwei Biotech, highlighting its safety, tolerability, and efficacy in patients with moderate to severe chronic obstructive pulmonary disease (COPD) [2][4]. Group 1: Drug Overview - 9MW1911 is an innovative monoclonal antibody developed using a high-efficiency B lymphocyte screening platform, targeting the ST2 receptor to block the IL33/ST2 signaling pathway [2]. - The drug has completed a Phase IIa clinical study involving 80 patients with moderate COPD, with a Phase IIb trial expected to start in July 2025 after enrolling at least 120 participants [2][3]. Group 2: Clinical Trial Results - The Phase IIa study (9MW1911-C03) was a randomized, double-blind, placebo-controlled trial assessing safety, tolerability, pharmacokinetics, and preliminary efficacy [3]. - Results indicated that all dosage groups of 9MW1911 showed good safety and tolerability compared to the placebo group, with an adverse event rate of 70% versus 85% for the placebo [4]. - The annualized rate of acute exacerbations in moderate COPD patients decreased by over 30% at the recommended Phase IIb dose compared to the placebo, and the rate of severe exacerbations decreased by over 40% [2][4].

Group 1: Company Overview and Leadership - Anke Bioengineering has strategic partnerships with companies like Boshengji, Afana, and Yuansong Bio, focusing on innovative drug development and commercialization [3][4][5][6] - The leadership team includes Chairman and President Song Lihua, Vice Chairman Zhou Yuanyuan, and several vice presidents overseeing various departments [2][3] Group 2: Research and Development Highlights - Boshengji's CAR-T PA3-17 has entered critical clinical trial phases, aiming for full patient enrollment by Q1 2027 and pre-NDA communication submission [3] - Yuansong Bio's lead product, recombinant L-IFN adenovirus injection, has progressed to Phase IIa clinical trials in China [5] - Afana has received clinical trial approvals for six Class I new drugs, focusing on autoimmune diseases and mRNA therapies, with significant advancements in CAR-T and HPV treatments [6][7] Group 3: Product Pipeline and Market Strategy - The company is advancing a long-acting growth hormone, expected to be approved by the end of 2025, with a focus on leveraging its commercial capabilities [4][8] - The long-acting follicle-stimulating hormone has begun market entry, with ongoing efforts to establish partnerships with private hospitals for sales [9] - The dual-target Her2 and PD-L1*4-1BB antibodies are in clinical development, with plans for IND submission in 2027 [10][11] Group 4: Financial and Market Positioning - The company aims to maintain stable growth in its traditional business while expanding into innovative drug markets [11] - Strategic focus on optimizing product structure and enhancing market competitiveness through accelerated commercialization and R&D capabilities [11] - The company is developing a comprehensive 3, 5, and 10-year strategic plan to address market challenges and enhance its positioning in the capital market [11]

Core Insights - The article highlights the rise of female entrepreneurs in China, particularly focusing on Zeng Fangqin, the CEO of Lingyi iTech, who is referred to as the "Invisible Queen" in the precision manufacturing sector. The company is preparing for an IPO on the Hong Kong Stock Exchange, with a market value of 95 billion yuan [1][8]. Company Overview - Lingyi iTech, founded by Zeng Fangqin in 2006, has grown from a small factory with 80 employees to a publicly listed company with a market capitalization of 95 billion yuan [4][5]. - The company has established itself as a key player in the Apple supply chain, with over 60% of its revenue coming from Apple-related businesses, including a 70% share of the iPhone 17 Pro stainless steel frame orders [3][5]. Financial Performance - Lingyi iTech's revenue for 2022-2024 is projected to be 34.5 billion yuan, 34.2 billion yuan, and 44.26 billion yuan, respectively, with net profits of 1.57 billion yuan, 2.02 billion yuan, and 1.76 billion yuan during the same period [5][6]. - In the first nine months of 2025, the company achieved a revenue of 37.59 billion yuan, with a record quarterly revenue of 139.65 billion yuan in Q3, marking a year-on-year growth of 12.91% [6]. Strategic Expansion - The company has diversified its client base beyond Apple to include major players like Huawei and Tesla, aided by strategic acquisitions since its reverse merger in 2018 [6][7]. - Notable acquisitions include the purchase of 100% of Saierkang Group for approximately 2.15 billion yuan in 2019, which expanded its customer resources in the consumer electronics charging equipment sector [6][7]. Future Growth Initiatives - Zeng Fangqin announced a strategic focus on bipedal robots, planning to invest at least 200 million yuan annually over the next three years to become a top three manufacturer in the field [7]. - The company aims to provide a comprehensive solution for humanoid robot components, collaborating with AI robotics firms to enhance its technological capabilities [7]. Industry Context - The article emphasizes the broader trend of female entrepreneurs in China, with Zeng Fangqin's achievements paralleling those of other notable figures like Zhong Huijuan of Hansoh Pharmaceutical and Zhou Qunfei of Lens Technology, showcasing the growing influence of women in the business landscape [8][9].

Core Viewpoint - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for the clinical trial of GenSci142 capsules, marking the first new drug clinical trial application approved under the newly introduced "30-day channel" for innovative drug clinical trials in China [1][2] Group 1: Regulatory Changes - The National Medical Products Administration (NMPA) implemented a 60-day implied approval system in 2019, reducing the review cycle to approximately 50 working days, which accelerated the development of innovative drugs in China [2] - The introduction of the "30-day channel" aims to meet clinical needs and enhance the international competitiveness of China's innovative drugs, allowing eligible clinical trial applications to be reviewed within 30 working days [2] Group 2: Product Details - GenSci142 capsules are a first-class innovative biological product developed by Jinsai Pharmaceutical, intended for the treatment of bacterial vaginosis (BV), a common vaginal infection among women of childbearing age [3] - The existing treatments for BV rely on antibiotics like metronidazole, which have high resistance rates (up to 90%) and high recurrence rates, highlighting the need for new solutions [3] Group 3: R&D Investment and Strategy - Changchun High-tech has significantly increased its R&D investment, with R&D expenses reaching 1.733 billion yuan in the first three quarters of 2025, supporting a rich pipeline of innovative products [3] - The company is leveraging AI technology throughout its R&D process, enhancing efficiency from target discovery to clinical trial design, which provides a competitive edge in the innovative drug development race [4] - The company aims to build a diversified product matrix and focuses on developing innovative drugs in areas such as endocrine metabolism, immunity, oncology, and women's health [4]

证券代码：002317 编号：2025-013 广东众生药业股份有限公司投资者关系活动记录表 | | √ □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） 平安证券股份有限公司、长城证券股份有限公司、东莞证券股 | | | 份有限公司、易米基金管理有限公司、东莞市私募基金业协 会、秋水高通私募基金管理（上海）有限公司、深圳市麻王投 资集团有限公司、盛世恒瑞（广东）投资有限公司、深圳市明 | | | 华信德私募证券基金管理有限公司、南通熙宁投资管理有限 | | | 公司、国城资本有限公司、广州中科粤创孵化器投资管理有限 | | | 公司、深圳市梦工场投资管理有限公司、广州明玥私募证券投 | | 参与单位及人员 | 资基金管理有限公司、东莞市哥们私募证券投资基金管理有 | | | 限公司、广东众帮投资有限公司、东莞市鼎和私募证券投资管 | | | 理有限公司、广西世安医疗科技有限公司、衣食住行私募证券 | | | 投资管理（广东）有限公司、东莞市 ...